Skip to main content
Top
Published in: BMC Infectious Diseases 1/2016

Open Access 01-12-2015 | Research article

HPV Vaccine utilization, Alberta 2008/09 – 2013/14 School year

Authors: Xianfang C. Liu, Christopher A. Bell, Kimberley A. Simmonds, Margaret L. Russell, Lawrence W. Svenson

Published in: BMC Infectious Diseases | Issue 1/2016

Login to get access

Abstract

Background

In Canada both bivalent (bHPV) vaccine and quadrivalent HPV vaccine (qHPV) are authorized for use. In Alberta, while both vaccines are available for private purchase, only qHPV is publicly funded for school girls in grades 5 and 9 as of 2013. We describe HPV vaccine uptake in Alberta, by school year, from the start of the publicly funded program in the Fall of 2008 through to August 31st 2014 and estimate the cumulative proportion of the female population who were vaccinated by the end of the 2013/14 school year.

Methods

We used data from the Alberta Ministry of Health Immunization and Adverse Reaction to Immunization repository (publicly funded vaccine), the population-based Pharmaceutical Information Network information systems (privately purchased vaccine) for the period September 1, 2008 to August 31, 2014 and demographic data from the Alberta Health Care Insurance Plan Registry. We estimate vaccine uptake rates and explore them by attributes of person, time, place, vaccine funding, and number of doses received. We estimated the cumulative proportions of the female population (by age group and number of doses received) who had received HPV vaccine by the end of the 2013/14 school year.

Results

Of the 169,259 unique individuals who received one or more doses of HPV vaccine over the period, 98.3 % were females, and 83.8 % received publicly funded vaccines. Vaccine uptake increased over the period. The cumulative proportion of females aged 9–26 years as of 2013/14 who had received two or more doses of vaccine was 34.3 %; for those aged 10–11 years 59.6 % and for those aged 14–15 years, 76.0 %. For those aged 9–26 years, 31.3 % had received three doses of vaccine.

Conclusion

HPV vaccine uptake rates have increased in Alberta over the study period, most prominently among the age groups targeted by the publicly funded school-girl vaccine program.
Literature
5.
go back to reference Russell ML, Dover DC, Simmonds KA, Svenson LW. Shingles in Alberta: Before and after publicly funded varicella vaccination. Vaccine. 2014;32(47):6319–24. Russell ML, Dover DC, Simmonds KA, Svenson LW. Shingles in Alberta: Before and after publicly funded varicella vaccination. Vaccine. 2014;32(47):6319–24.
6.
go back to reference Liu X, Simmonds K, Russell M, Svenson L. Herpes zoster vaccine (HZV): utilization and coverage 2009–2013, Alberta, Canada. BMC Public Health. 2014;14(1):1098. Liu X, Simmonds K, Russell M, Svenson L. Herpes zoster vaccine (HZV): utilization and coverage 2009–2013, Alberta, Canada. BMC Public Health. 2014;14(1):1098.
10.
go back to reference Brisson M, van de Velde N, Franco EL, Drolet M, Boily MC. Incremental Impact of Adding Boys to Current Human Papillomavirus Vaccination Programs: Role of Herd Immunity. J Infect Dis. 2011;204(3):372–6. Brisson M, van de Velde N, Franco EL, Drolet M, Boily MC. Incremental Impact of Adding Boys to Current Human Papillomavirus Vaccination Programs: Role of Herd Immunity. J Infect Dis. 2011;204(3):372–6.
Metadata
Title
HPV Vaccine utilization, Alberta 2008/09 – 2013/14 School year
Authors
Xianfang C. Liu
Christopher A. Bell
Kimberley A. Simmonds
Margaret L. Russell
Lawrence W. Svenson
Publication date
01-12-2015
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2016
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-016-1340-6

Other articles of this Issue 1/2016

BMC Infectious Diseases 1/2016 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.